The Next Bubble?

One of the next bubbles to hit may be genomics, says Alex Planes at The Motley Fool. The field is growing quickly, Planes notes, with more and more companies coming online and treatments and diagnostics starting to make their way to market — all driven by the steep decline of sequencing costs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.